Abstracts tagged "Mouse Models, Other"

Abstract Number: 1883 • ACR Convergence 2022
Auto-antibodies Targeting Membrane Repair Proteins Enhances Myositis Phenotype
Shane Bruckner¹, Kassidy Banford², hannah Bulgart², Kevin mcElhanon³, Rohit Aggarwal⁴, Chester Oddis⁵, Noah Weisleder¹ and Wael Jarjour¹, ¹The Ohio State University, Columbus, OH, ²The Ohio State University Wexner Medical Center, Columbus, OH, ³Pfizer Inc., Cambridge, MA, ⁴Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ⁵University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of disorders in which autoimmune responses produce a chronic state of inflammation resulting in degeneration of skeletal…
Abstract Number: 2021 • ACR Convergence 2022
Early Histopathological Changes of the Salivary Glands Associated with the Development of Primary Sjögren’s Syndrome
Xiaomei Shan¹, Clara Reichardt¹, Jeeshan Singh¹, Anne Zeitler², Christine Schauer¹, Jasmin Knopf¹, Martin Herrmann¹, Gerhard Grossmayer¹, Georg Schett¹ and Luis Munoz¹, ¹Universitätsklinikum Erlangen, Erlangen, Germany, ²Friedrich-Alexander University Erlangen Nürnberg, Erlangen, Germany
Background/Purpose: Primary Sjögren's syndrome (PSS) is a chronic inflammatory disease affecting exocrine glands including salivary and lacrimal glands that leads to dry eyes and mouth…
Abstract Number: 2263 • ACR Convergence 2022
Nanotherapeutic Approaches for the Treatment of Post-traumatic Osteoarthritis
Luke Springer¹, Kelsey Collins², Huimin Yan², Ying Hu³, Farshid Guilak², Samuel Wickline⁴, Hua Pan² and Christine Pham², ¹Washington University School of Medicine, St. Louis, MO, ²Washington University School of Medicine, Saint Louis, MO, ³Washington University, Saint Louis, MO, ⁴University of South Florida, Tampa, FL
Background/Purpose: Osteoarthritis (OA) represents the most common form of arthritis and is a major cause of morbidity in the aging population. Post-traumatic OA (PTOA) is…
Abstract Number: 0004 • ACR Convergence 2022
mTORC1 Drives the Spectrum of Pathology in Systemic JIA and Macrophage Activation Syndrome
zhengping huang¹, xiaomeng You², Liang Chen³, Yan Du³, Kailey Brodeur³, Qiang Wang³, David Sykes⁴, Margaret Chang⁵, Julia Charles², Peter Nigrovic⁵ and Pui Lee⁵, ¹Guangdong Second Provincial Hospital, Guangzhou, China, ²Brigham and Women's Hospital, Boston, MA, ³Boston Children's Hospital, Boston, MA, ⁴Massachusetts General Hospital, Boston, MA, ⁵Division of Immunology, Boston Children's Hospital, Boston, MA
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a severe inflammatory syndrome characterized by fever, skin rash and arthritis. A subset of patients with sJIA develop…
Abstract Number: 0024 • ACR Convergence 2022
Exposure to Pollutants with Endocrine Disrupting Properties Is Associated with Early Cartilage Defects and Chondrocyte Inflammatory and Oxidative Activation
Sabryne Berkani¹, Inés Kouki², Sylvie Babajko³, Audrey Pigenet⁴, padmaja Natarajan⁵, Philip Ordoukhanian⁶, Xavier Houard⁴, Martin Lotz⁷, Barbara Demeneix⁸, Jean-Baptiste Fini⁸, Francis Berenbaum⁹, Jérémie SELLAM¹⁰ and Alice Courties¹¹, ¹Sorbonne Université, INSERM UMR 938, Centre de Recherche Saint-Antoine, Department of Rheumatology, Assistance Publique , Hôpital Saint-Antoine, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France, Paris, ²Sorbonne Université, INSERM UMR 938, Centre de Recherche Saint-Antoine, Department of Rheumatology, Assistance Publique , Hôpital Saint-Antoine, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ³Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Paris, France, Paris, ⁴Sorbonne Université, INSERM UMR 938, Centre de Recherche Saint-Antoine, Hôpital Saint-Antoine, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France, Paris, ⁵Center for Computational Biology & Bioinformatics and Genomics Core, Scripps Research, La Jolla, California, USA, La Jolla, ⁶Center for Computational Biology & Bioinformatics and Genomics Core, Scripps Research, La Jolla, CA, ⁷Scripps Research, La Jolla, ⁸UMR 7221, Phyma, CNRS-Muséum National d'Histoire Naturelle, Sorbonne Université, 75005 Paris, France., Paris, ⁹Sorbonne University - Saint-Antoine hospital, Paris, France, ¹⁰Sorbonne Universite, AP-HP, Saint-Antoine hospital, Paris, France, ¹¹Service de Rhumatologie, AP-HP Hopital Saint-Antoine, Sorbonne Universite, INSERM, Centre de Recherche Saint-Antoine, Paris, France, Paris, France
Background/Purpose: Humans are exposed to pollutants with endocrine disruptors (ED) properties from their in utero life. Among them, a mix of 15 pollutants (perfluorinated compounds,…
Abstract Number: 0178 • ACR Convergence 2022
Muscle Fibres Play a Critical Role in Therapeutic Response of Myositis to Glucocorticoids Through Polarisation of the Inflammatory Infiltrate by a Paracrine Mechanism
Margherita Giannini¹, Daniela Rovito², Léa Debrut³, Céline Keime⁴, Beatrice Lannes⁵, Anne-Laure Charles³, Delphine Duteil², Bernard Geny⁶, Daniel Metzger², Gilles Laverny² and Alain Meyer¹, ¹Service de Physiologie et explorations fonctionnelles, CHU, Strasbourg ; Centre de Référence des Maladies Autoimmunes Rares, CHU, Strasbourg ; UR3072, Centre de Recherche en Biomédecine, University of Strasbourg, Strasbourg, France, ²University of Strasbourg, CNRS UMR7104, INSERM U1258, IGBMC, F-67400, Illkirch, France, ³UR3072 Centre de Recherche en Biomédecine, University of Strasbourg, Strasbourg, France, ⁴University of Strasbourg, CNRS UMR 7104, INSERM UMR-S 1258, IGBMC, F-67400, Illkirch, France, ⁵Département de pathologie, Centre de référence des maladies neuromusculaires, CHU Strasbourg, University of Strasbourg, Strasbourg, France, ⁶Service de Physiologie et explorations fonctionnelles, CHU, Strasbourg ; UR3072 Centre de Recherche en Biomédecine, University of Strasbourg, Strasbourg, France
Background/Purpose: Glucocorticoids (GC) are the first line treatment for myositis patients. They improve muscle strength, yet muscle recovery is generally partial and long lasting treatment…
Abstract Number: 0560 • ACR Convergence 2022
IL-17 Regulates Apolipoprotein E in Lymph Node Stromal Cells During Infection and Autoimmunity
Catherine Poholek¹ and Mandy McGeachy², ¹UPM Children's Hospital of Pittsburgh/University of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Autoimmune disease (AID) resulting from a dysregulated immune response is associated with substantial morbidity and mortality, largely driven by cardiovascular disease (CVD)/atherosclerosis and dyslipidemia.…
Abstract Number: 1478 • ACR Convergence 2021
An Orphan Receptor and Osteoarthritis: Mouse Gpr34 Expression in Dorsal Root Ganglia After Partial Meniscectomy
David Thomas¹, Terese Geraghty², Alia Obeidat², Jun Li², Rachel Miller² and Anne-Marie Malfait³, ¹University of Minnesota Internal Medicine Residency, St. Paul, MN, ²Rush University Medical Center, Chicago, IL, ³Rush University, Chicago, IL
Background/Purpose: Osteoarthritis (OA) is one of the leading causes of musculoskeletal pain and disability. Worldwide, an estimated 303 million patients have clinically diagnosed OA, with…
Abstract Number: 1513 • ACR Convergence 2021
Control of T Cell Tolerance by the NR4A Family of Nuclear Receptors
Ryosuke Hiwa¹, Hailyn Nielsen¹, James Mueller¹ and Julie Zikherman², ¹University of California San Francisco, San Francisco, CA, ²UCSF Medical Center, San Francisco, CA
Background/Purpose: Current therapies for autoimmune disease often lead to treatment-limiting immunosuppression. Selective manipulation of antigen (Ag)-specific immune responses could enhance our therapeutic approach. Targeting members…
Abstract Number: 0173 • ACR Convergence 2020
mTORC1 Signaling Promotes Monocytosis and Arthritis Development in IL-1 Receptor Antagonist-deficient Mice
Zhengping Huang¹, Ying Li², Alexandra Wactor³, Peter Nigrovic⁴ and Pui Lee⁵, ¹1.Guangdong Second Provincial General Hospital;2.Brigham and Women's Hospital;3.Harvard Medical School, BOSTON, MA, ²1.Brandeis University;2.Brigham and Women's Hospital, Waltham, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, Boston, ⁵1.Boston Children's Hospital;2.Brigham and Women's Hospital;3.Harvard Medical School, Newton, MA
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is potentially life-threatening disease characterized by prolonged fever, systemic inflammation and skin rash in addition to joint inflammation. Aberrant…
Abstract Number: 0469 • ACR Convergence 2020
IFNγ Is Essential for Alveolar Macrophage Driven Lung Inflammation in Macrophage Activation Syndrome
Denny Gao¹, Maggie Henderlight¹, Christopher Woods¹, Alexei Grom¹, Sherry Thornton¹, Michael Jordan¹, Katheryn Wikenheiser-Brokamp¹ and Grant Schulert², ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: Macrophage activation syndrome (MAS) is a life-threatening cytokine storm syndrome frequently complicating systemic juvenile idiopathic arthritis (SJIA) and driven by IFNγ. MAS is also…
Abstract Number: 0703 • ACR Convergence 2020
Liraglutide as a Potential Intra-Articular Treatment for Cartilage Regeneration in Osteoarthritis: In Vitro and In Vivo Studies Supporting a Pro-Chondrogenic Effect
Francis Berenbaum¹, Coralie Meurot², Laure Sudre³, Keren Bismuth², Revital Rattenbach², Patrice Denefle², Celine Martin² and Claire Jacques³, ¹AP-HP, Hôpital Saint-Antoine, Service de Rhumatologie, Centre de Recherche Saint-Antoine, INSERM UMR_S 938,Sorbonne Université, Paris, 75012, France, Paris, France, ²Campus Institut Pasteur Lille, 4P Pharma, Lille, France, ³Inserm, UMR_S938, Hospital Saint-Antoine, Paris, France
Background/Purpose: Osteoarthritis (OA) is an age-related joint disease affecting millions of individuals worldwide and associated with an extremely high burden largely attributable to disability. To…
Abstract Number: 1077 • ACR Convergence 2020
Glucagon-like Peptide-1 Receptor Agonist Suppresses Muscle Inflammation and Muscle Fiber Death, and Ameliorates Muscle Weakness in Experimental Polymyositis
Mari Kamiya¹, Seon Uk Kim², Jeong Yeon Kim³, Shinsuke Yasuda⁴, Eun Young Lee⁵ and Fumitaka Mizoguchi¹, ¹Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ²Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Jongno-gu, Seoul, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, ⁴Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Tokyo, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
Background/Purpose: Glucocorticoids (GC) are the cornerstone of the treatment for polymyositis (PM). However, the treatment with GC causes GC-induced myopathy, which further deteriorates the muscle…
Abstract Number: 1401 • ACR Convergence 2020
Disease Mutation That Weakens ZAP70 Autoinhibition Enhances Responses to Weak and Self Ligands
Lin Shen¹, Mehrdad Matloubian¹, Theresa Kadlecek² and Arthur Weiss¹, ¹University of California, San Francisco, San Francisco, CA, ²University of California, San Francisco, San Francisco
Background/Purpose: ZAP70, a cytoplasmic protein tyrosine kinase, is critical for TCR signaling and T cell development. Complete loss of function of ZAP70 in humans causes…
Abstract Number: 1575 • ACR Convergence 2020
CD6 Is a Target for Cancer Immunotherapy
Jeffrey Ruth¹, Mikel Gurrea Rubio², Kalana Athukorala³, Stephanie Rasmussen¹, Weber Daniel¹, Peggy Randon¹, M Asif Amin¹, Phillip Campbell¹, Pei-suen Tsou¹, Yang Mao-Draayer¹, Qi Wu⁴, Matthew Lind¹, Rosemary Gedert¹, Thomas Lanigan¹, Venkateshwar Keshamouni¹, Nora Singer⁵, Feng Lin⁶ and David Fox⁷, ¹University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan, Canton, MI, ³University of Michigan, Ann Arbor, MN, ⁴University of Michigan, Ann Arbor, ⁵The MetroHealth System, Case Western Reserve University School of Medicine, Cleveland, OH, ⁶Cleveland Clinic Foundation, Cleveland, OH, ⁷Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Limitations of checkpoint inhibitor immunotherapy include induction of autoimmune syndromes and resistance of many cancers. Definition of additional molecular targets is required. CD6, expressed…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].